Eli Lilly halts late stage trial into Covid-19 antibody treatment, but 'confident' it works
Eli Lilly and Company
$762.66
10:59 18/03/24
Eli Lilly and researchers at the National Institutes of Health have paused a late-stage clinical trial into a combination of the company's antibody treatment against Covid-19 in combination with Gilead Science's Remdesivir in severely ill patients.
Gilead Sciences Inc.
$73.26
12:29 18/03/24
Nasdaq 100
17,985.01
12:15 18/03/24
The decision came after determining that there was "insufficient evidence" that the combined treatment was unlikely to prove effective.
It also followed a pause in the trial two weeks before due to a potential safety concern.
Nevertheless, the treatment was now deemed to be safe and the drug giant said it was "confident" that the therapy could keep Covid-19 from progressing to more severe stages.
Indeed, other trials to ascertain just that were set to continue, including a phase two study of non-hospitalised patients who had recently been diagnosed with the infection and a phase three study looking into its potential benefits for residents and staff at hospitals.
The company's assertion regarding the treatment's efficacy was based on data from its phase two study.